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Objectives: The aim of this retrospective study is to compare surgical margins, reoperation rates and local
recurrences after breast conserving surgery (BCS) using radioguided occult lesion localization (ROLL) or
radioactive seed localization (RSL).
Materials and methods: We reviewed 744 consecutive patients with impalpable primary invasive breast
cancer who underwent BCS at Helsinki University Hospital between 2010 and 2012. ROLL was used in our
unit until October 31st, 2011; from November 1st we changed localization method to RSL.
Results: 318 patients underwent ROLL and 426 RSL. Patients in the RSL group had more often multifocal
(p¼ 0.013) tumours. No statistically significant differences were found regarding tumour size, specimen
weight, histology or grade of tumours or lymph node status. 42 (5.6%) patients were reoperated because
of insufficient margins, 13 (4.1%) in the ROLL group and 29 (6.8%) in the RSL group. The reoperation rate
was not different between the groups either in the univariable analysis (p¼ 0.112) or in the multivariable
binary logistic regression analysis (p¼ 0.204). Risk factors for reoperations were multifocality of the
tumour (p < 0.001), extensive intraductal component (p < 0.001), larger tumour size (p¼ 0.011), and
smaller specimen weight (p¼ 0.014). The median follow-up time in the ROLL group was 81 (8e94)
months and 64 (3e73) months in the RSL group. The five-year local recurrence-free survival (LRFS)
estimates for ROLL and RSL groups were 98.0% and 99.4%, respectively (log-rank test, p¼ 0.323).
Conclusion: Reoperation rates and LRFS were comparable for ROLL and RSL in patients with impalpable
breast cancer treated with BCS.
© 2019 Elsevier Ltd. All rights reserved.1. Introduction
The number of impalpable malignant breast tumours has
increased due to improved imaging and screening programmes.
Breast conserving surgery (BCS) in patients with impalpable tu-
mours requires precise preoperative lesion localization to ensure
adequate surgical margins. Furthermore, the aim in BCS is to ach-
ieve good aesthetic result by minimizing the amount of resected
healthy breast tissue [1].mprehensive Cancer Center,
S, Finland.
ki).Wire-guided localization (WGL) has been the gold standard for
surgical excision of impalpable breast lesions. There are, however,
some downsides with WGL. It has rates of incomplete surgical
excision ranging from 12% to 60% [2e5]. Furthermore, WGL is un-
pleasant for patient and scheduling of wire insertion and surgery
can be challenging. Therefore, other localization methods have
been introduced.
Radioguided occult lesion localization (ROLL) is a technique
using albumin particles labelled with radioactive technetium (Tc-
99m), which is injected before surgery intra- or peritumorally
under ultrasound (US) or stereotactic guidance. Intraoperatively a
gamma probe is used to detect the radioactivity; the same probe is
used for sentinel lymph node biopsy (SLNB).
Abbreviations
BCS Breast conserving surgery
WGL Wire-guided localization
ROLL Radioguided occult lesion localization
US Ultrasound
SLNB Sentinel lymph node biopsy
RSL Radioactive seed localization
LR Local recurrence
DCIS Ductal carcinoma in situ
RT Radiotherapy
CNB Core needle biopsy
FNAC Fine needle aspiration cytology
MRI Magnetic resonance imaging
MDT Multidisciplinary team
CT Computed tomography scan
LRFS local recurrence-free survival
EIC Extensive intraductal component
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125 econtaining titanium seed, also inserted under US or stereo-
tactic guidance into the center of the tumour. The tumour and the
seed can be detected intraoperatively accurately using gamma
probe likewise. RSL can be performed well ahead of surgery with
flexible scheduling, since the half-life of iodine-125 is significantly
longer compared to technetium-99m (60 days vs. 6 h) [5].
There are several studies comparing ROLL or RSL to WGL [6e8]
but only few comparing ROLL and RSL [9e11]. The aim of this
retrospective study is to compare surgical margins, reoperation
rates and local recurrences (LR) after BCS using ROLL and RSL.2. Material and methods
1876 consecutive patients with primary invasive breast cancer
or ductal carcinoma in situ (DCIS) who underwent BCS at Breast
Surgery Unit of Helsinki University Hospital between the January
1st, 2010 and December 31st, 2012 were reviewed for this retro-
spective cohort study. None of the patients received neoadjuvant
treatment.
We excluded patients who underwent a lumpectomy with
neither adjuvant treatment nor axillary surgery due to comorbid-
ities, patients who had been diagnosed by surgical biopsy and those
whose breast cancer was found unexpectedly in reduction mam-
moplasty specimen. Furthermore, we excluded patients with
palpable tumours, those who underwent other localization pro-
cedure than ROLL or RSL and patients with pure DCIS. In the
remaining 744 patients, tumours were localized using either ROLL
or RSL (Fig. 1).
ROLLwas used in our unit until October 31st, 2011, since thenwe
used RSL. During the ROLL era, WGL was used for large area of
microcalcifications and for multifocal tumours. In addition, WGL
was used in DCIS, when there was no need for SLNB. During the RSL
eraWGLwas used only occasionally. In total, there were 93 patients
with pure DCIS; 13 of them underwent ROLL and 30 RSL. Due to the
small number of eligible DCIS cases, especially in the ROLL group,
the analysis for pure DCIS cases was performed separately.
Patient, tumour, treatment and follow-up data was collected
from electronic patient records. Synchronous bilateral cancer was
regarded as two separate cases when assessing primary surgical
outcome. Bilateral disease was excluded from the survival analysis.2.1. Imaging
All patients underwent preoperative mammography and breast
and axillary US. Core needle biopsy (CNB) was taken from breast
lesion(s) and fine needle aspiration cytology (FNAC) from suspi-
cious axillary lymph nodes. Patients who had an invasive lobular
carcinoma diagnosed on CNB underwent magnetic resonance im-
aging (MRI).
2.2. Tumour localization technique
The image-guided localization was performed or supervised by
experienced breast radiologists. Both ROLL and RSL were per-
formed under US or stereotactic guidance, dependent upon the
visibility of the tumour. In ROLL, a single peritumoural 100e120
MBq Tc-99m nanocolloid injection was used and utilized for the
SLNB. A lymphoscintigraphy with dual-head gamma camera was
obtained 1.5e3 h after injection to exclude leakage and to identify
the sentinel nodes. The RSL was performed within four weeks prior
to surgery. Iodine-125-radiolabeled seeds (Oncura, RAPID Strand,
Arlington Heights,Ill, USA) were used. The 4.5 by 0.8mm titanium-
encapsulated seedwas placed inside an 18-gauge needle and aimed
at the center of the tumour. A two-view mammography (cranio-
caudal and lateromedial) was performed to confirm correct place-
ment of the seed.
During surgery, the seed or the nanocolloid was localized using
a handheld gamma probe and the tumour area was excised. A
specimen radiography was routinely performed to assess the
radiological margins and in case of RSL, to confirm the presence of
the seed. Specimen US was performed whenever needed, at the
discretion of the breast radiologist.
2.3. Surgical technique
All breast and axillary operations were performed or supervised
by experienced breast surgeons. Surgeon decided on the operation
technique individually depending on the location and size of the
tumour, as well as on the size and the glandular density of breast, in
agreement with the patient. In this study, conventional BCS stands
for resection of the tumour with adequate mobilization and closure
of breast tissue. Oncoplastic BCS instead refers to other level 1 and
level 2 oncoplastic procedures [12,13].
Patients with axillary lymph node metastasis in US guided FNAC
underwent axillary lymph node dissection. SLNB was performed in
remaining patients.
Reoperation due to inadequate margins was either a re-excision
or a mastectomy and was dependent on breast size, glandular
density and aesthetic result after the first operation, with patient's
preference taken into account. The guidelines for adequate surgical
margins changed at the beginning of the study period in 2010, the
new recommendations were adopted in our unit gradually. Previ-
ously 5mm microscopical histological margins were required for
invasive cancer and 10mm for DCIS. Consensus symposium in 2010
recommended that no ink on tumour is adequate for invasive
cancer and 2mm for DCIS [14]. At our unit, the recommended DCIS
margins were applied for margins of the intraductal component in
patients with invasive cancer.
2.4. Histopathological examination
Histopathological analyses from surgical specimens were per-
formed by experienced breast pathologists. The breast and lymph
node specimens were handled and examined as described in our
earlier study [15].
Fig. 1. Patient inclusion flowchart.
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All cases were discussed at a multidisciplinary team (MDT)
meeting after surgery in order to recommend adjuvant treatment.
All patients received postoperative RT except thosewho underwent
mastectomy as a second operation and those who were not fit for
RT or refused RT. Patients who had distant metastases identified on
postoperative whole body computed tomography scan (CT) did not
receive RT either. Adjuvant chemotherapy and endocrine treatment
were recommended according to the Finnish national evidence-
based guidelines [16]. The RT and adjuvant systemic treatment
protocols used at our institution are described in our earlier study
[17].
2.6. Follow-up
The first clinical checkup took placewithin threeweeks after the
operation. After adjuvant treatment, the patients were followed-up
at the Department of Oncology of Helsinki University Hospital for
5e10 years, according to the risk of recurrence. The follow-up
consisted of visits at least at one, three and five years after the
operation.
Mammography was performed annually, combined with US in
women 45 years of age, in women with high density of breast in
mammography or if needed as further diagnostic investigation.
Annual breast MRI was performed inwomenwith hereditary breast
cancer. Additionally, MRI, whole body CT or bone isotope scanwere
performed whenever indicated for instance due to symptoms
which might indicate local or distant recurrence.
In addition, all patients had an access to an outpatient clinic
whenever there were concerns regarding symptoms related to side
effects of treatments or potential recurrence.
After the first 5e10 years, the follow-up continued at primary
health care, according to regional guidelines.
2.7. Statistical analyses
Statistical analyses were performed using IBM™ SPSS™ Statis-
tics version 22 software (SPSS Inc., Chicago, IL). Frequency tables
were analyzed with chi-squared test and continuous distributions
with Mann-Whitney U test.
Independent variables with p-values < 0.15 in the univariable
analyses were entered into a backward stepwise binary logistic
regression analysis to evaluate their association with need for
reoperation due to insufficient margins in a multivariable model. At
each step of the analysis, the variable with the highest p-value was
eliminated until the remaining variables had p-values < 0.05.
For breast cancer events, we excluded patients with bilateral
disease (n¼ 51), earlier breast cancer (n¼ 28), other malignancy
(apart from DCIS or basal cell carcinoma) within five years (n¼ 44),
distant metastasis diagnosed within 12 months after primary
operation (n¼ 2) and those who underwent a completion mas-
tectomy (n¼ 26). In addition, we excluded patients who were
followed-up for less than three years due to migration to other
hospital district (n¼ 14).
The remaining 579 patients went through a Kaplan-Meier sur-
vival analysis for local recurrence-free survival (LRFS), and the ROLL
and RSL groups were compared with the log-rank test. Other breast
cancer events were assessed with Fisher's exact test simply
comparing event counts.
3. Results
The patient and tumour characteristics are summarized in
Table 1 as well as adjuvant therapy. ROLL was performed in 318(42.7%) patients and RSL in 426 (57.3%). The patients in the ROLL
group were slightly younger (p¼ 0.033). The median tumour size
was 10mm (1e40mm) in the ROLL group and 11mm (1e55mm) in
the RSL group (p¼ 0.219). There were no differences between the
groups regarding pT1a-c subgroups (p¼ 0.815).
Histological subtypes were distributed similarly in the groups
(p¼ 0.469), but the tumours in the ROLL group had higher prolif-
eration index Ki-67 (p¼ 0.031). Patients in the RSL group had more
often multifocal (p¼ 0.013) tumours; 60 (14.1%) tumours in the RSL
group were multifocal compared to 26 (8.2%) in the ROLL group. No
significant differences between the ROLL and RSL groups were
found regarding specimenweight, grade of tumours or lymph node
status.
79 (24.8%) patients in ROLL group and 120 patients (28.2%) in
the RSL group underwent oncoplastic BCS (p¼ 0.311). Various
oncoplastic techniques were used and the amount of resected tis-
sue varied substantially depending on the surgical technique (range
8e1893 g) [13].
More patients in the RSL group received adjuvant endocrine
treatment.
3.1. Reoperations
Surgical margins were wider in the ROLL group, though the
median of the smallest lateral surgical margin was 10mm in the
both groups (p¼ 0.011) (Table 1). However, there was no statisti-
cally significant difference in insufficient surgical margins or
reoperation rate between the groups (p¼ 0.112) in the univariable
analysis. 42 (5.6%) patients were reoperated because of insufficient
margins, 13 (4.1%) in the ROLL group and 29 (6.8%) in the RSL group
(Table 2).
Risk factors for reoperations in the univariable analysis were
multifocality of the tumour (p< 0.001) and extensive intraductal
component (EIC) (p< 0.001). Altogether, 86 patients had multifocal
tumours, 18 (20.9%) of them underwent a reoperation, compared to
24 (3.6%) out of 658 patients with unifocal tumours. Twelve (20.0%)
patients out of 60 with EIC underwent a reoperation compared to
30 (4.4%) out of 684 without EIC.
In the multivariable binary logistic regression analysis multi-
focality of the tumour (p< 0.001) and EIC (p< 0.001) remained risk
factors for reoperation (Table 3). Furthermore, larger tumour size
(p¼ 0.011) and smaller specimen weight (p¼ 0.014) were statisti-
cally significant factors predicting a reoperation. There was no
statistically significant difference in the reoperation rate between
the ROLL and RSL (p¼ 0.204) in the multivariable binary logistic
regression analysis either.
The second operation was a re-excision for 11 patients (26.2%)
and mastectomy for 31 (73.8%). Five patients underwent a re-
excision in the ROLL group and six in the RSL group, a completion
mastectomywas performed in eight patients in the ROLL group and
in 23 the RSL group (p¼ 0.226).
3.2. Breast cancer recurrence
Altogether 579 patients remained for survival analysis of LRFS,
258 in the ROLL group and 321 in the RSL group (Table 4). The
median follow-up time in the ROLL group was 81 (8e94) months
and 64 (3e73)months in the RSL group. Seven (2.7%) patients in the
ROLL group developed an ipsilateral LR and three (0.9%) in the RSL
group. The five-year LRFS estimates for ROLL and RSL groups were
98.0% and 99.4%, respectively (log-rank test, p¼ 0.323, Fig. 2).
All breast cancer events are summarized in Table 4. Distant
metastases were detected in three (1.2%) patients in the ROLL group
and likewise in three (0.9%) in the RSL group (Fisher's test,
p¼ 1.000).
Table 1
Patient and tumour characteristics for ROLL and RSL.
ROLL N¼ 318 (42.7%) RSL N¼ 426 (57.3%) p-value
N % N %
Surgery Conventional BCS 239 75.2% 306 71.8% 0.311
Oncoplastic BCS 79 24.8% 120 28.2%
Reoperation due to insufficient margins No 305 95.9% 397 93.2% 0.112
Yes 13 4.1% 29 6.8%
Reoperation Re-excision 5 38.5% 6 20.7% 0.226
Mastectomy 8 61.5% 23 79.3%
Histology Invasive ductal carcinoma 230 72.3% 291 68.3% 0.469
Invasive lobular carcinoma 39 12.3% 63 14.8%
Other invasive 49 15.4% 72 16.9%
Pathological T stage pT1 304 95.6% 400 93.9% 0.461
pT2 14 4.4% 25 5.9%
pT3 0 0.0% 1 .2%
Multifocal tumour No 292 91.8% 366 85.9% 0.013
Yes 26 8.2% 60 14.1%
EIC 0 287 90.3% 397 93.2% 0.145
1 31 9.7% 29 6.8%
Tumour grade 1 145 45.6% 203 47.7% 0.444
2 130 40.9% 156 36.6%
3 43 13.5% 67 15.7%
ER Negative 22 7.0% 26 6.1% 0.644
Positive 294 93.0% 399 93.9%
PR Negative 77 24.4% 103 24.2% 0.967
Positive 239 75.6% 322 75.8%
Ki-67 0e15% 216 69.0% 308 72.5% 0.031
16e30% 58 18.5% 88 20.7%
>30% 39 12.5% 29 6.8%
HER-2 Negative 296 93.7% 391 92.0% 0.387
Positive 20 6.3% 34 8.0%
Lymph node status pN0 259 81.4% 330 77.5% 0.243
pN1mic 24 7.5% 31 7.3%
pN1mac 35 11.0% 65 15.3%
Radiotherapy No 10 3.1% 20 4.7% 0.288
Yes 308 96.9% 406 95.3%
Adjuvant treatment No 101 31.8% 95 22.3% 0.020
Endocrine treatment 141 44.3% 226 53.1%
Chemotherapy 8 2.5% 16 3.8%
Both 68 21.4% 89 20.9%
Median (range) Median (range)
Age (years) 62 (38e83) 64 (36e91) 0.033
Tumour size (mm) 10 (1e40) 11 (1e55) 0.219
Smallest lateral surgical margin (mm) 10 (0e30) 10 (0e40) 0.011
Specimen weight (g) 55 (12e996) 60 (8e1893) 0.142
Abbreviations: ROLL, radioguided occult lesion localization; RSL, radioactive seed localization; BCS, breast conserving surgery; EIC, extensive intraductal component.
ER, estrogen receptor; PR, progesterone receptor; Ki-67, proliferation marker; HER-2, human epidermal growth factor receptor.
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ROLL group and eight (2.5%) in the RSL group (Fisher's test,
p¼ 0.250). Only one (0.4%) patient in ROLL group and two (0.6%) in
the RSL group died from breast cancer (Fisher's test, p¼ 1.000).
3.3. Patients with pure DCIS
The results for patients with DCIS are summarized in Table 5.
ROLL was performed only in 13 cases and RSL in 30. There was no
statistically significant differences between the groups regarding
size, multifocality or grade of DCIS, or regarding reoperation rates
or adjuvant treatment.
4. Discussion
4.1. Main message
This study showed that ROLL and RSL provided similar outcomes
regarding insufficient margin status, reoperation rates and LRFS in
patients with impalpable invasive breast cancer treated with BCS.
Instead of localization method, the risk factors for reoperations
were multifocality of the tumour, larger tumour size, EIC andsmaller specimen weight. This is consistent with previous studies
[11,13]. There were more multifocal tumours in the RSL group. ROLL
was not used in our unit if the tumour was multifocal in preoper-
ative imaging; previously patients with multifocal lesions under-
went WGL.
4.2. Reoperations
In our series, the reoperation rate due to insufficient margins
was low (5.6%) compared to previous studies of ROLL or RSL. In the
systematic review and meta-analysis by Lovrics et al. [4] the
reoperation rate after ROLL excision was 6.2e33.3% and after RSL
7.8e9.6%. In more recent studies the reoperation rate after both
ROLL and RSL has shown to be 7e13% [5,9e11,18e20]. Velazco et al.
though, showed lower re-excision rate in their study of RSL
(2.3e4.1%) [21]. Insufficient surgical margins and indications for
reoperation are variable in the studies, making the comparison of
studies difficult.
There are only few previous studies comparing ROLL and RSL.
Van der Noordaa et al. compared these two localization techniques
in their study [9] and did not find significant difference in reoper-
ation rates (ROLL 10% vs. RSL 9%). Neither did Donker et al. [10], who
Table 2
Patient and tumour characteristics for reoperations due to inadequate margins.
Reoperation due to inadequate margins
Yes No p-value
N¼ 42 (5.6%) N¼ 702 (94.4%)
N % N %
Localization method ROLL 13 31.0% 305 43.4% 0.112
RSL 29 69.0% 397 56.6%
Reoperation Re-excision 11 26.2% 0 0.0%
Mastectomy 31 73.8% 0 0.0%
Histology Invasive ductal carcinoma 28 66.7% 493 70.2% 0.863
Invasive lobular carcinoma 6 14.3% 96 13.7%
Other invasive 8 19.0% 113 16.1%
Multifocal tumour N 24 57.1% 634 90.3% <0.001
Ye 18 42.9% 68 9.7%
EIC 0 30 71.4% 654 93.2% <0.001
1 12 28.6% 48 6.8%
Tumour grade 1 13 31.0% 335 47.7% 0.107
2 21 50.0% 265 37.7%
3 8 19.0% 102 14.5%
ER Negative 5 11.9% 43 6.2% 0.141
Positive 37 88.1% 656 93.8%
PR Negative 13 31.0% 167 23.9% 0.300
Positive 29 69.0% 532 76.1%
Ki-67 0e15% 27 65.9% 497 71.3% 0.491
16e30 11 26.8% 135 19.4%
>30% 3 7.3% 65 9.3%
HER-2 Negativ 36 85.7% 651 93.1% 0.072
Positiv 6 14.3% 48 6.9%
Lymph node status pN0 28 66.7% 561 79.9% 0.095
pN1mic 4 9.5% 51 7.3%
pN1mac 10 23.8% 90 12.8%
Median (range) Median (range)
Age (years) 64 (36e85) 62 (38e91) 0.243
Tumour size (mm) 13 (1e40) 10 (1e55) 0.112
Specimen weight (g) 50 (12e298) 58 (8e1893) 0.055
Abbreviations: ROLL, radioguided occult lesion localization; RSL, radioactive seed localization; EIC, extensive intraductal component.
ER, estrogen receptor; PR, progesterone receptor; Ki-67, proliferation marker; HER-2, human epidermal growth factor receptor.
Table 3
Risk factors for reoperation using binary logistic regression analysis.
OR 95% C.I. for OR p-value
Lower Upper
Lymph node status pN0 1 0.900
pN1mic 1.185 0.333 4.223 0.793
pN1mac 1.226 0.476 3.155 0.673
HER-2 Negative 1
Positive 1.506 0.445 5.095 0.510
ER Negative 1
Positive 0.498 0.128 1.945 0.316
Tumour grade 1 1 0.294
2 1.880 0.849 4.163 0.119
3 1.382 0.465 4.113 0.560
Localization method ROLL 1
RSL 1.614 0.771 3.381 0.204
Multifocal tumour No 1
Yes 8.968 4.263 18.866 <0.001
EIC No 1
Yes 6.214 2.626 14.702 <0.001
Tumour size 1.077 1.017 1.140 0.011
Specimen weight 0.988 0.979 0.998 0.014
Abbreviations: OR, odds ratio; C.I. confidence interval; HER-2, human epidermal growth factor receptor; ER, estrogen receptor.
ROLL, radioguided occult lesion localization; RSL, radioactive seed localization; EIC, extensive intraductal component.
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RSL 8%). Theunissen et al. [11] compared all WGL, ROLL and RSL and
they found that RSL results in a higher negative surgical margin rate
and lower reoperation rate.4.3. Specimen weight
In this study we did not find any difference in specimen weight
between the ROLL and RSL (p¼ 0.143), similarly to other previously
published studies [9e11]. Our study material includes all patients
Table 4
Breast cancer events observed during follow-up.
ROLL (N¼ 258) RSL (N¼ 321) p-value (Fisher)
Follow-up time, median (range) 81 (8e94) months 64 (3e73) months
Event N (%) N (%)
Ipsilateral breast recurrence 7 (2.7%) 3 (0.9%) 0.119
Contralateral breast recurrence 3 (1.2%) 2 (0.6%) 0.660
Regional lymph node recurrence 3 (1.2%) 1 (0.3%) 0.329
Ipsilateral axillaa 1 (0.4%) 1 (0.3%)
Contralateral axillab 1 (0.4%) 0
Supraclavicular nodec 1 (0.4%) 0
Distant metastasis 3 (1.2%) 3 (0.9%) 1.000
Death from breast cancer 1 (0.4%) 2 (0.6%) 1.000
Death from any cause 11 (4.3%) 8 (2.5%) 0.250
Abbreviations: ROLL, radioguided occult lesion localization; RSL, radioactive seed localization.
a The patients in both groups had concomitant LR.
b The patient had concomitant LR and distant metastasis.
c The patient had concomitant distant metastasis.
Fig. 2. Kaplan-Meier survival analysis for local recurrence-free survival after breast conserving surgery using radioguided occult lesion localization (ROLL) or radioactive seed
localization (RSL).
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resection, therefore there is a wide range in specimen weights. We
did not evaluate specimen volumes, since determining tumour-
resection volume ratio in large oncoplastic resection specimens is
not relevant.
In our study, the RSL group included more often multifocal
disease and this possibly increased the specimen weights of thegroup. However, larger specimen weights may not result in poorer
aesthetic result in the era of oncoplastic surgery, which is used
more and more in our unit [22].4.4. Local recurrences
In our series, there was no difference in the estimated five-year
Table 5
ROLL and RSL for DCIS cases.
ROLL N¼ 13 (30.2%) RSL N¼ 30
(69.8%)
p-value
N % N %
Surgery Conventional BCS 8 61.5% 23 76.7% 0.310
Oncoplastic BCS 5 38.5% 7 23.3%
Reoperation due to insufficient margins No 12 92.3% 25 83.3% 0.435
Yes 1 7.7% 5 16.7%
DCIS multifocality No 12 92.3% 25 83.3% 0.435
Yes 1 7.7% 5 16.7%
DCIS grade 1 1 7.7% 2 6.7% 0.405
2 3 23.1% 14 46.7%
3 9 69.2% 13 43.3%
NA 0 0.0% 1 3.3%
Radiotherapy No 2 15.4% 1 3.3% 0.154
Yes 11 84.6% 29 96.7%
Adjuvant treatment Endocrine treatment 0 0.0% 1 3.3% 0.497
Endocrine treatment and chemotherapya 0 0.0% 2 6.7%
Ipsilateral breast recurrence 0 0.0% 1 3.3% 0.505
Median (range) Median (range)
Age (years) 60 (49e83) 58 (43e88) 0.276
DCIS histological size (mm) 10 (4e30) 12 (3e40) 0.936
Abbreviations: DCIS, ductal carcinoma in situ; ROLL, radioguided occult lesion localization.
RSL, radioactive seed localization; BCS, breast conserving surgery; NA, Not available.
a Chemotherapy due to contralateral invasive breast cancer.
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studies reporting LR rates after BCS using ROLL or RSL. Theunissen
et al. [11] reported a LR rate of 6.6% in the ROLL group (median
follow-up 51months) and no recurrences in the RSL group (median
follow-up 33 months). A recent study by Aljohani et al. [19] re-
ported a LR of only 0.3%, but the median follow-up time was just 37
months in the RSL group.
Contralateral breast cancer recurrences, regional lymph node
recurrences and breast cancer deaths were rare in our study.
4.5. Strengths and limitations of the study
In this study, we reviewed a large number of patients. This is a
single-center study, the diagnostic and treatment protocols,
including surgical practice, are standardized at our institution.
A limitation of this study is that data was collected retrospec-
tively. Consequently, the RSL group patients had more often
multifocal disease and received more often endocrine treatment,
perhaps partly due to the multifocality, as there was no difference
in tumour sizes. In addition, we excluded DCIS from the main
analysis due to the small number of cases, especially in the ROLL
group. DCIS is a known risk factor for positive margins and this may
bias our findings. Among DCIS patients, we did not find statistically
significant differences between ROLL and RSL, neither in the DCIS
characteristics nor in the reoperation rate, possibly due the very
small number of patients.
Furthermore, the guidelines for adequate surgical margins
changed at the beginning of the study period in 2010. The new
recommendation ‘no ink on tumour’ was introduced gradually,
hence the indication for reoperation is not standard throughout the
study period and was favoring RSL.
4.6. Other aspects of ROLL and RSL
Even though we did not find any difference in surgical outcome
or oncological safety between ROLL and RSL, there are some clear
advantages with RSL. The seeds are visible in mammography and
their correct positioning is easy thus to confirm. RSL might also
provide more accurate localization, since there is a risk of disper-
sion of Tc-99m during the injection for ROLL. With RSL, it ispossible to mark multiple lesions or a large microcalcification area
with 2e3 seeds, which is a clear advantage compared to ROLL.
RSL provides flexible scheduling and logistics, since the seed can
be placed weeks or even several months before surgery, for
example in patients undergoing neoadjuvant treatment. It is quite
common that when inserting the seed, the radiologist detects
another suspicious lesion not identified in earlier imaging and bi-
opsies or even re-planning of surgerymay be needed [5]. Hence, we
schedule the RSL well before operation.
On the other hand, due to the long half-life of I-125 seed, careful
handling and disposal protocols are needed [9]. An advantage of
ROLL is that it can be performed simultaneously with SNLB using a
single injection of radiolabeled colloid [23,24].
4.7. Future aspects
Because WGL, ROLL and RSL have all some disadvantages,
several new localization methods have been developed [24e26].
Non-ionizing markers using magnetic technology and radio-
frequency energy are already in clinical use as well as intra-
operative US. In addition, many other techniques are under
investigation. Long-term evidence is needed to evaluate the feasi-
bility of these new localization methods.
5. Conclusion
ROLL and RSL provided similar surgical outcomes in terms of
margin status, reoperation rates and LRFS in patients with impal-
pable invasive breast cancer treated with BCS.
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